{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:48:46Z","timestamp":1788972526875,"version":"build-2803163510"},"reference-count":62,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Psoriasiform dermatitis refers to a spectrum of inflammatory skin disorders that resemble psoriasis both clinically and histologically. These conditions can occur idiopathically or as paradoxical reactions to biologic or targeted therapies, particularly in patients with atopic or autoimmune backgrounds. Histologic features often include acanthosis, parakeratosis, and lymphocytic infiltrates, but without the full molecular signature of classical psoriasis. This review provides an overview of psoriasiform dermatitis with a focus on its clinical presentation, differential diagnosis, and the immune pathways involved. Drug-induced forms, especially those triggered by anti-TNF agents, IL-4\/IL-13 blockers, and JAK inhibitors, are highlighted due to their growing clinical relevance. We also summarize the main topical and systemic treatments, including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and JAK-STAT- or IL-23-targeted therapies. A better understanding of psoriasiform dermatitis is crucial to improve diagnosis and to guide treatment, especially in complex or refractory cases.<\/jats:p>","DOI":"10.3390\/life15071026","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T03:54:28Z","timestamp":1751255668000},"page":"1026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-2443","authenticated-orcid":false,"given":"Eugenia Veronica","family":"Di Brizzi","sequence":"first","affiliation":[{"name":"Dermatology Unit, University of Campania \u201cL. Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7433-9283","authenticated-orcid":false,"given":"Stefano","family":"Caccavale","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania \u201cL. Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2148-8914","authenticated-orcid":false,"given":"Caterina Mariarosaria","family":"Giorgio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania \u201cL. Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-8214","authenticated-orcid":false,"given":"Giuseppe","family":"Argenziano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania \u201cL. Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania \u201cL. Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.semdp.2016.12.006","article-title":"Psoriasiform dermatitides: A brief review","volume":"34","author":"Wick","year":"2017","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ali, K., Wu, L., Qiu, Y., and Li, M. (2022). Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab. Front. Med., 9.","DOI":"10.3389\/fmed.2022.932766"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., and Fang, H. (2020). The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.594735"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jdermsci.2024.06.002","article-title":"Topical application of a BCL-2 inhibitor ameliorates imiquimod-induced psoriasiform dermatitis by eliminating senescent cells","volume":"115","author":"Zhu","year":"2024","journal-title":"J. Dermatol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1007\/s10620-015-3763-0","article-title":"Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease","volume":"60","author":"George","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1111\/jdv.16280","article-title":"A case of Atopic dermatitis and Hidradenitis Suppurativa successfully treated with Dupilumab","volume":"34","author":"Gambardella","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/ced\/llae208","article-title":"Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: A real-world multicentre Italian study of 2576 patients","volume":"49","author":"Ferrucci","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ced\/llae162","article-title":"Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis","volume":"49","author":"Napolitano","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Salvi, I., Parodi, A., Cozzani, E., and Burlando, M. (2024). Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1432233"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.jid.2024.01.004","article-title":"LPCAT1 Facilitates Keratinocyte Hyperproliferation and Skin Inflammation in Psoriasis by Regulating GLUT3","volume":"144","author":"Huang","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdcr.2024.04.021","article-title":"Cytokine-pathway blockers worsen mycosis fungoides masquerading as psoriasis","volume":"48","author":"Blanchard","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Liu, J., Qiu, C., Zhou, Z., Li, J., Zhen, Y., Wang, R., Zhuang, Y., and Zhang, F. (2024). Pentraxin 3 exacerbates psoriasiform dermatitis through regulation of macrophage polarization. Int. Immunopharmacol., 130.","DOI":"10.1016\/j.intimp.2024.111805"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Popa, L.G., Giurcaneanu, C., Portelli, M.G., Mihai, M.M., Beiu, C., Orzan, O.A., Ion, A., and Anghel, T.H. (2024). Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice. Medicina, 60.","DOI":"10.3390\/medicina60030373"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bezdek, S., Leng, L., Busch, H., Mousavi, S., Rades, D., Dahlke, M., Zillikens, D., Bucala, R., and Sadik, C.D. (2018). Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasiform Dermatitis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02262"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1172\/JCI133159","article-title":"KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease","volume":"130","author":"Billi","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1016\/j.jid.2018.05.018","article-title":"Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis","volume":"138","author":"Killeen","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1111\/jdv.18648","article-title":"A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis","volume":"37","author":"Stingeni","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/pde.14820","article-title":"Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children","volume":"38","author":"Parker","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Patruno, C., Fabbrocini, G., De Lucia, M., Picone, V., Genco, L., and Napolitano, M. (2022). Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib. Dermatol. Ther., 35.","DOI":"10.1111\/dth.15788"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/path.6162","article-title":"Forward genetics and functional analysis highlight Itga11 as a modulator of murine psoriasiform dermatitis","volume":"261","author":"Bieber","year":"2023","journal-title":"J. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2147\/CCID.S336072","article-title":"The Interactions of Small Proline-Rich Proteins with Late Cornified Envelope Proteins are Involved in the Pathogenesis of Psoriasis","volume":"14","author":"Tian","year":"2021","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mehta, S., Singal, A., Singh, N., and Bhattacharya, S.N. (2009). A study of clinicohistopathological correlation in patients of psoriasis and psoriasiform dermatitis. Indian. J. Dermatol. Venereol. Leprol., 75.","DOI":"10.4103\/0378-6323.45241"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Di Brizzi, E.V., Buononato, D., Benvenuto, P., Argenziano, G., De Pasquale, R., Fiorella, C.S., Gioffr\u00e8, C., Musumeci, M.L., Palazzo, G., and Zichichi, L. (2023). Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis. Dermatol. Pract. Concept., 13.","DOI":"10.5826\/dpc.1304a215"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Ibba, L., Ingurgio, R.C., Malagoli, P., Amoruso, F., Balato, A., Bardazzi, F., Brianti, P., Brunasso, G., and Burlando, M. (2024). Comparative effectiveness of tildrakizumab 200\u2009mg versus tildrakizumab 100\u2009mg in psoriatic patients with high disease burden or above 90\u2009kg of body weight: A 16-week multicenter retrospective study-IL PSO (Italian landscape psoriasis). J. Dermatol. Treat., 35.","DOI":"10.1080\/09546634.2024.2350760"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0560.1985.tb00439.x","article-title":"Psoriasiform and related papulosquamous disorders","volume":"12","author":"Barr","year":"1985","journal-title":"J. Cutan. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1525-1470.1999.00099.x","article-title":"Psoriasiform acral dermatitis: A peculiar clinical presentation of psoriasis in children","volume":"16","author":"Patrizi","year":"1999","journal-title":"Pediatr. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2340\/0001555572206207","article-title":"Psoriasiform acral dermatitis. Report of three cases","volume":"72","author":"Tosti","year":"1992","journal-title":"Acta Derm. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.det.2013.06.008","article-title":"Dermoscopy in general dermatology","volume":"31","author":"Lallas","year":"2013","journal-title":"Dermatol. Clin."},{"key":"ref_30","first-page":"e153","article-title":"Clinical and dermoscopic features of pleomorphic dermal sarcoma","volume":"60","author":"Moscarella","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5826\/dpc.0902a13","article-title":"Pigmented Squamous Cell Carcinoma: Is the Reported Prevalence Real?","volume":"9","author":"Corneli","year":"2019","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sutarjono, B., and Lebovitch, H. (2019). Psoriasiform spongiotic dermatitis. BMJ Case Rep., 12.","DOI":"10.1136\/bcr-2018-228690"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/exd.14691","article-title":"Reflectance confocal microscopy in paediatric patients: Applications and limits","volume":"32","author":"Scharf","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Benvenuto, P., Tancredi, V., Ronchi, A., Scharf, C., Fulgione, E., and Moscarella, E. (2025). In Vivo Characterization of the Inflammatory Infiltrate in Discoid Lupus Erythematosus (DLE) by Line-Field Confocal Optical Coherence Tomography (LC-OCT). Dermatol. Pract. Concept., 15.","DOI":"10.5826\/dpc.1501a5089"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mao, J., Du, N., Jia, Y., Mao, Q., Yang, J., Zhang, Y., Li, Y., Cao, L., and Min, W. (2024). Case report: Treatment of psoriasiform dermatitis in patients with malignancy. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1363405"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1684\/ejd.2021.4140","article-title":"Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment","volume":"31","author":"Kurihara","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2023.05.001","article-title":"Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response","volume":"110","author":"Jiang","year":"2023","journal-title":"J. Dermatol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wang, P., Killeen, M.E., Sumpter, T.L., Ferris, L.K., Falo, L.D., Freeman, B.A., Schopfer, F.J., and Mathers, A.R. (2021). Electrophilic nitro-fatty acids suppress psoriasiform dermatitis: STAT3 inhibition as a contributory mechanism. Redox Biol., 43.","DOI":"10.1016\/j.redox.2021.101987"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jdermsci.2021.04.004","article-title":"Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes","volume":"102","author":"Okura","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Chan, T.C., Lee, M.-S., Huang, W.-C., Chang, W.-Y., Krueger, J.G., and Tsai, T.-F. (2021). Capsaicin attenuates imiquimod-induced epidermal hyperplasia and cutaneous inflammation in a murine model of psoriasis. Biomed. Pharmacother., 141.","DOI":"10.1016\/j.biopha.2021.111950"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tancredi, V., Buononato, D., Caccavale, S., Di Brizzi, E.V., Di Caprio, R., Argenziano, G., and Balato, A. (2023). New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010362"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdcr.2024.05.009","article-title":"Upadacitinib for the treatment of psoriasiform and spongiotic dermatitis: A multicenter case series","volume":"49","author":"Shahriari","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Cirone, K.D., and Lovegrove, F.E. (2025). Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report. SAGE Open Med. Case Rep., 13.","DOI":"10.1177\/2050313X251317811"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Foggia, L., Potestio, L., Patruno, C., di Vico, F., and Napolitano, M. (2025). Reply to: Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: A case series. Int. J. Dermatol., 64.","DOI":"10.1111\/ijd.17594"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/JIR.S412418","article-title":"Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report","volume":"16","author":"Zhong","year":"2023","journal-title":"J. Inflamm. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/09546634.2019.1673877","article-title":"Off-label studies on tofacitinib in dermatology: A review","volume":"32","author":"Tegtmeyer","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_49","first-page":"495","article-title":"Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis","volume":"40","author":"Zerilli","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jdermsci.2021.08.001","article-title":"Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis","volume":"104","author":"Uchida","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Orsini, D., Megna, M., Assorgi, C., Balato, A., Balestri, R., Bernardini, N., Bettacchi, A., Bianchelli, T., Bianchi, L., and Buggiani, G. (2024). Efficacy and Safety of bimekizumab in elderly patients: Real-world multicenter retrospective study-IL PSO (Italian Landscape Psoriasis). J. Dermatol. Treat., 35.","DOI":"10.1080\/09546634.2024.2393376"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/jdv.20143","article-title":"Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study","volume":"38","author":"Chiricozzi","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1089\/derm.2023.0208","article-title":"Interleukin-17 Monoclonal Antibody Successfully Treated Psoriasiform Drug Eruption Induced by Immune Checkpoint Inhibitors: A Case Report and Review of Literature","volume":"35","author":"Li","year":"2024","journal-title":"Dermatitis"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Li, Q., Li, X., Li, W., Fan, R., Ma, Q., Luo, X., Jian, H., Chen, X., Cao, C., and Zheng, W. (2024). Development of IL-17A inhibitor-induced atopic dermatitis-like rash in psoriasis patients: Insights into immune shift. Exp. Dermatol., 33.","DOI":"10.1111\/exd.14958"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/cup.13952","article-title":"Drug-induced psoriasiform alopecia associated with interleukin-17 inhibitor therapy","volume":"48","author":"Tan","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14712598.2020.1727439","article-title":"Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: A case series and review of the literature","volume":"20","author":"Caldarola","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Megna, M., Balato, A., Caccavale, S., Cacciapuoti, S., Calabrese, G., Di Brizzi, E.V., Di Costanzo, L., Manzo, R., Marino, V., and Puca, R.V. (2024). Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13092552"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Zhou, L., Wang, Y., Wan, Q., Wu, F., Barbon, J., Dunstan, R., Gauld, S., Konrad, M., Leys, L., and McCarthy, R. (2021). A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs, 13.","DOI":"10.1080\/19420862.2021.1964420"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdermsci.2019.07.006","article-title":"Anti-IL-17A and IL-23p19 antibodies but not anti-TNF\u03b1 antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis","volume":"95","author":"Shimizu","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Li, L., Wu, Z., Wu, M., Qiu, X., Wu, Y., Kuang, Z., Wang, L., Sun, T., Liu, Y., and Yi, S. (2020). IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis. Int. Immunopharmacol., 89.","DOI":"10.1016\/j.intimp.2020.107008"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Strecker, M., Wlotzka, K., Strassheimer, F., Roller, B., Ludmirski, G., K\u00f6nig, S., R\u00f6der, J., Opitz, C., Alekseeva, T., and Reul, J. (2022). AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. Oncoimmunology, 11.","DOI":"10.1080\/2162402X.2022.2127508"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.9740\/mhc.2018.03.049","article-title":"Overcoming barriers to monitoring patients taking second-generation antipsychotics","volume":"8","author":"DeJongh","year":"2018","journal-title":"Ment. Health Clin."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:00:25Z","timestamp":1760032825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["life15071026"],"URL":"https:\/\/doi.org\/10.3390\/life15071026","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}